ANIP
NASDAQANI Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings11
News · 26 weeks74-65%
2025-10-262026-04-19
Mix5590d
- Insider41(75%)
- Other6(11%)
- SEC Filings6(11%)
- Earnings2(4%)
Latest news
25 items- PRANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT ExclusivityPRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap®. "We are proud to announce the launch of Pimozide Tablets with 180-Day CGT exclusivity. We are excited to bring limited competition products to market and continue to provide generic alternatives to our customers and patients," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. U.S. annual sales for Pimozide Tablets total approximately $3.1 million, based on February 2026 moving annual total (MAT) IQVIA data. A
- INSIDERSEC Form 4 filed by Cook Meredith4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- PRANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release CapsulesPRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI's Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol®. "Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "The launch of Carbamazepine Extended-Release Capsules, another limited competition product, highlights our continued commitment to improving patient access to essential medicines whil
- SECSEC Form DEFA14A filed by ANI Pharmaceuticals Inc.DEFA14A - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- SECSEC Form DEF 14A filed by ANI Pharmaceuticals Inc.DEF 14A - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate TabletPRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI's Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket®. "We are pleased to announce FDA approval and launch of Isosorbide Mononitrate Tablet USP, which highlights our efforts to bring limited-competition products to market and ensure that our high-quality products are readily accessible to our customers and patien
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in OphthalmologyPRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a corticosteroid indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ANI Pharmaceuticals Inc.SCHEDULE 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
- INSIDERHEAD OF RARE DISEASE Mutz Christopher sold $226,526 worth of shares (3,162 units at $71.64), decreasing direct ownership by 3% to 91,309 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew sold $357,471 worth of shares (4,772 units at $74.91), decreasing direct ownership by 11% to 38,730 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $36,310 worth of shares (500 units at $72.62), decreasing direct ownership by 0.63% to 79,390 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERHEAD OF RARE DISEASE Mutz Christopher sold $424,617 worth of shares (5,723 units at $74.19) and covered exercise/tax liability with 3,314 shares, decreasing direct ownership by 9% to 94,471 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERPRESIDENT & CEO Lalwani Nikhil covered exercise/tax liability with 17,060 shares, decreasing direct ownership by 4% to 404,889 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, GENERICS Gutwerg Ori covered exercise/tax liability with 3,314 shares, decreasing direct ownership by 4% to 81,468 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, CHIEF HR OFFICER Davis Krista sold $488,474 worth of shares (6,572 units at $74.33), decreasing direct ownership by 11% to 51,946 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP & CFO Carey Stephen P. covered exercise/tax liability with 5,150 shares, decreasing direct ownership by 3% to 180,393 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP & CFO Carey Stephen P. exercised 3,312 shares at a strike of $49.51 and sold $552,031 worth of shares (7,312 units at $75.50), decreasing direct ownership by 2% to 185,543 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERHEAD OF RARE DISEASE Mutz Christopher sold $30,858 worth of shares (417 units at $74.00), decreasing direct ownership by 0.40% to 103,508 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, GENERICS Gutwerg Ori sold $157,590 worth of shares (2,060 units at $76.50), decreasing direct ownership by 2% to 84,782 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Walsh Patrick D sold $445,380 worth of shares (6,000 units at $74.23), decreasing direct ownership by 10% to 52,405 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- INSIDERHEAD OF R&D, COO-NOVITIUM OPS Shanmugam Muthusamy was granted 11,116 shares, increasing direct ownership by 12% to 101,056 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew was granted 6,021 shares and covered exercise/tax liability with 628 shares, increasing direct ownership by 14% to 43,502 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERHEAD OF RARE DISEASE Mutz Christopher was granted 21,306 shares and covered exercise/tax liability with 2,221 shares, increasing direct ownership by 22% to 103,925 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)